Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being... Show more
A.I.dvisor indicates that over the last year, UPC has been loosely correlated with BIOA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if UPC jumps, then BIOA could also see price increases.
| Ticker / NAME | Correlation To UPC | 1D Price Change % | ||
|---|---|---|---|---|
| UPC | 100% | -2.71% | ||
| BIOA - UPC | 50% Loosely correlated | -7.78% | ||
| HCM - UPC | 22% Poorly correlated | +0.56% | ||
| TXMD - UPC | 22% Poorly correlated | -2.70% | ||
| CRON - UPC | 13% Poorly correlated | -2.76% | ||
| CTOR - UPC | 13% Poorly correlated | -17.16% | ||
More | ||||
| Ticker / NAME | Correlation To UPC | 1D Price Change % |
|---|---|---|
| UPC | 100% | -2.71% |
| Pharmaceuticals: Generic industry (83 stocks) | 2% Poorly correlated | +123.01% |
Industry PharmaceuticalsGeneric
The Moving Average Convergence Divergence (MACD) for UPC turned positive on October 22, 2026. Looking at past instances where UPC's MACD turned positive, the stock continued to rise in 41 of 44 cases over the following month. The odds of a continued upward trend are 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where UPC's RSI Indicator exited the oversold zone, 35 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on UPC as a result. In 80 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
Following a +24.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where UPC advanced for three days, in 179 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
UPC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
UPC moved below its 50-day moving average on September 21, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UPC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for UPC entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.808) is normal, around the industry mean (9.012). P/E Ratio (-0.001) is within average values for comparable stocks, (-3.044). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.150) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. UPC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UPC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.